Disorders of sex development: a genetic study of patients in a multidisciplinary clinic

**Luigi Laino, Silvia Majore, Nicoletta Preziosi, Barbara Grammatico,
Carmelilia De Bernardo, Salvatore Scommegna¹, Anna Maria Rapone²,
Giacinto Marrocco³, Irene Bottillo and Paola Grammatico**

Department of Molecular Medicine, Medical Genetics, San Camillo-Forlanini Hospital, Sapienza University, A.O. San Camillo-Forlanini, Padiglione Morgagni, I piano, UOC Laboratorio di Genetica Medica, Circonvallazione Gianicolense 87, Rome 00152, Italy

¹Department of Pediatrics and Hematology, San Camillo-Forlanini Hospital, A.O. San Camillo-Forlanini, Padiglione Baccelli, II piano, Pediatria ed Ematologia Pediatrica, Circonvallazione Gianicolense 87, Rome 00152, Italy

²Psychology Department, San Camillo-Forlanini Hospital, A.O. San Camillo-Forlanini, Dipartimento di Psicologia, Circonvallazione Gianicolense 87, Rome 00152, Italy

³Department of Pediatric Surgery, San Camillo-Forlanini Hospital, A.O. San Camillo-Forlanini, Padiglione Baccelli, II piano, Pediatria ed Ematologia Pediatrica, Circonvallazione Gianicolense 87, Rome 00152, Italy

Correspondence
should be addressed
to I Bottillo

Email
i.bottillo@gmail.com

Abstract

Sex development is a process under genetic control directing both the bi-potential gonads to become either a testis or an ovary, and the consequent differentiation of internal ducts and external genitalia. This complex series of events can be altered by a large number of genetic and non-genetic factors. Disorders of sex development (DSD) are all the medical conditions characterized by an atypical chromosomal, gonadal, or phenotypical sex. Incomplete knowledge of the genetic mechanisms involved in sex development results in a low probability of determining the molecular definition of the genetic defect in many of the patients. In this study, we describe the clinical, cytogenetic, and molecular study of 88 cases with DSD, including 29 patients with 46,XY and disorders in androgen synthesis or action, 18 with 46,XX and disorders in androgen excess, 17 with 46,XY and disorders of gonadal (testicular) development, 11 classified as 46,XX other, eight with 46,XX and disorders of gonadal (ovarian) development, and five with sex chromosome anomalies. In total, we found a genetic variant in 56 out of 88 of them, leading to the clinical classification of every patient, and we outline the different steps required for a coherent genetic testing approach. In conclusion, our results highlight the fact that each category of DSD is related to a large number of different DNA alterations, thus requiring multiple genetic studies to achieve a precise etiological diagnosis for each patient.

Key Words

- disorders of sex development
- DSD
- disorders of ovarian development
- disorders of testicular development

Endocrine Connections
(2014) 3, 180–192

Introduction

Sex development is a multistep process under genetic control, implying a delicate network of molecular events that direct both the bi-potential gonads to become either a

testis or an ovary (sex determination), and the consequent divergent differentiation of internal ducts and external genitalia (sex differentiation). Correct dimorphic sex

determination and differentiation achievement can be disrupted by a large number of genetic and non-genetic factors altering any of the molecular signals that specify sex-specific development of sex organs or endocrine function. The term disorders of sex development (DSD) embraces all the medical conditions characterized by an atypical chromosomal, gonadal, or phenotypical sex (1). Thus, a wide number of pathologies are included under the same DSD definition; they show different frequencies and their severity ranges from genital anomalies that do not impair sexual definition or functionality, such as hypospadias, to conditions characterized by sexual ambiguity or discordance between chromosomal and internal or external sex anatomy. In 2006, Hughes *et al.* (1) proposed the latest recommended classification of DSD, based on the sex chromosomal findings and on the step of gonadal development or phenotypic differentiation in which the alteration had occurred. Current understanding of the genetic control of sex development is still incomplete, resulting a low probability of determining the molecular definition of the causal defect in many of the patients with DSD. Anyhow, proper and thorough clinical evaluation and laboratory investigations are the necessary procedures for obtaining the most accurate diagnostic definition. This can more efficiently be achieved through a multidisciplinary assessment of patients performed by different dedicated specialists with long-standing experience and both pediatric and adult practice. In this study, we describe the results of studies carried out on 88 patients with DSD

evaluated and followed in the outpatient 'Centre for diagnosis, care and treatment of DSD' at San Camillo Forlanini Hospital, Sapienza University of Rome. In total, we found a genetic alteration in 56 out of 88 cases, leading to the correct clinical classification of every patient. Each category of DSD was found to be related to a large number of different DNA alterations, thus requiring multiple genetic studies to possibly achieve a precise etiological diagnosis in every patient.

Subjects and methods

Patients

A cohort of 88 individuals, aged from 1 day to 41 years affected by non-syndromic DSD, were fully evaluated at the DSD Centre of San Camillo-Forlanini Hospital, Rome (Italy), by an experienced multidisciplinary team including a pediatric surgeon, a pediatric endocrinologist, a clinical psychologist, and a clinical geneticist. Patients were identified on the basis of ambiguous genitalia or discordance among chromosomal, gonadal and/or phenotypic sex, or apparently minor genital abnormalities (Table 1, modified from Hughes *et al.* (1)). Patients in whom the presence of additional anomalies, such as dysmorphic features and skeletal or visceral abnormalities, was detected were excluded from the cohort with the exception of the three syndromic patients (cases 6, 27, and 32) included in the study. For each patient, hormonal, imaging, and

Table 1 Classification of the studied patients with DSD (based on Hughes *et al.* (1))

Sex chromosome DSDs	45,X (Turner's syndrome and variants) 47,XXY (Klinefelter syndrome and variants) 45,X/46,XY (mixed gonadal dysgenesis and ovotesticular DSD) 46,XX/46,XY (chimeric and ovotesticular DSD)
DSD 46,XX disorders of gonadal (ovarian) development	Ovotesticular DSDs Testicular DSDs Gonadal dysgenesis
DSD 46,XX androgen excess	Fetal 21 hydroxylase deficiency Fetal 11 hydroxylase deficiency Fetoplacental aromatase deficiency Maternal luteoma Exogenous androgen excess
DSD 46,XX other	MURCS, MRKH, and other syndromes
DSD 46,XY disorders of gonadal (testicular) development	Complete gonadal dysgenesis (Swyer syndrome) Partial gonadal dysgenesis Gonadal regression Ovotesticular DSDs
DSD 46,XY disorders in androgen synthesis or action	Androgen biosynthesis defect (5- α reductase deficiency) Defect in androgen action (androgen insensitivity syndrome) Disorders of <i>AMH</i> and <i>AMH</i> receptor (persistent Müllerian duct syndrome)

MURCS, Mullerian Renal Cervicothoracic Somite association; MRKH, Mayer Rokitsky Küster Hauser syndrome.

genetic investigations were carried out. Individuals showing 45,X, 47,XXX, and 47,XXY karyotypes, as well as 46,XX patients with gonadal dysgenesis and 46,XY patients with minor genital anomalies that did not give rise to any doubts about sex assignment, were excluded from the present report. In contrast, 46,XX female patients with developmental anomalies of the Müllerian duct were included in this cohort. In all cases, a stepwise clinical diagnostic approach for evaluation was conducted and psychological support was constantly provided to both patients and their families. The genetic analyses included the study of *AR*, *AMH*, *CYP11B1*, *CYP21A2*, *DHH*, *DMRT1*, *NROB1*, *NR5A1*, *RSPO1*, *SHOX*, *SOX9*, *SRD5A2*, *SRY*, and *WNT4* genes chosen on the basis of the data reported in the literature (2, 3, 4, 5). The genes analyzed for each patient were selected according to the DSD category. All enrolled individuals gave informed consent for DNA analyses, approved by local ethics committees in accordance with the guidelines of Italian Society of Human Genetics (SIGU).

Karyotyping

Metaphase spreads were obtained from blood lymphocytes using standard procedures. Chromosome analysis was performed using standard G-bands by trypsin using Giemsa (GTG)-banding techniques on cultured lymphocytes.

Testing the presence or absence of *SRY* gene

Recognition of the *SRY* sequence was carried out on genomic DNA through polymerase chain reaction (PCR) amplification with specific *SRY* and control (*ZP3*) gene primers as described by Cui et al. (6).

Fluorescent *in situ* hybridization

SRY translocations in 46,XX male patients and *DMRT1* deletions were investigated by fluorescent *in situ* hybridization (FISH) using two specific probes selected from a public database (<http://genome.ucsc.edu>), respectively, for *SRY* and *DMRT1* genes.

Direct sequencing

The search for DNA point mutations in *SRY*, *DHH*, *NR5A1*, *SRD5A2*, *AR*, *AMH*, *CYP21A2*, *CYP11B1*, *RSPO1*, and *WNT4* genes was carried out by PCR followed by direct sequencing. *SRD5A2*, *CYP21A2*, *AMH*, and *CYP11B1* were analyzed as described previously (7, 8, 9). Primer sequences and annealing temperatures employed for amplification

of *SRY*, *DHH*, *NR5A1*, *AR*, *RSPO1*, and *WNT4* coding sequences are listed in [Supplementary Table 1](#), see section on [supplementary data](#) given at the end of this article. Primers were designed in order to also detect possible splicing defects. Sanger sequencing was carried out using a BigDye Terminator v1.1 Cycle Sequencing Kit (Thermo Fisher Scientific, Waltham, MA, USA) on a 3500xl Genetic Analyzer (Thermo Fisher Scientific). Forward and reverse sequences were analyzed and compared with each gene's mRNA reference sequence: *SRY* (NM_003140.1), *DHH* (NM_010144), *NR5A1* (NM_004959), *SRD5A2* (NM_000348.3), *AR* (NM_000044.2), *AMH* (NM_000479), *CYP11B1* (NM_000497), *CYP21A2* (NM_000500), *RSPO1* (NM_001038633.2), and *WNT4* (NM_030761). All novel missense and splicing mutations were searched for in 200 control chromosomes from unaffected subjects.

CYP21A2 large deletions/conversions analysis

Investigation for large deletions/conversions affecting the *CYP21A2* gene was conducted as described by Lee et al. (10).

Multiplex ligation-dependent probe amplification (MLPA) analysis

Screening for single and multi-exonic deletions/duplications affecting *SOX9*, *NROB1*, *NR5A1*, *SRY*, *CYP21A2*, and *WNT4* genes was carried out using the MLPA SALSA P185-B2 Intersex (version 05; April 22, 2011) (MRC Holland, Amsterdam, The Netherlands), following the manufacturer's instructions. Information on probe sequences can be freely obtained from the MRC Holland website (www.mlpa.com). Relative quantification of copy number mutations was carried out using the Coffalyser Software (MRC Holland). DNA samples showing such a reduction or increase in the MLPA peak area values were reanalyzed by the same MLPA procedure. Only the samples showing consistent results between the two experiments were considered positive for a copy number alteration.

Real-time PCR

Copy number changes in *NROB1* genes identified by MLPA analyses and single/multi-exonic deletions/duplications of the *SHOX* gene were investigated using SYBR Green-based experiments on an ABI7900 HT Fast Real Time PCR System (Thermo Fisher Scientific). Primers were designed using the Primer Express 3.0 Software (Thermo Fisher Scientific; [Supplementary Table 2](#), see section on [supplementary data](#) given at the end of this article).

The reference gene telomerase reverse transcriptase (*TERT*) was simultaneously quantified in a separate tube for each specimen. For each primer pair, the reaction efficiency parameter (R2) was assessed by a standard-curve analysis as reported in [Supplementary Table 2](#). Results for each sample were expressed as N-fold changes in copies of each test exon, and normalized to *TERT* relative to the copy number of the test exon in the calibrator DNA, according to the following equation: amount of target = $2^{-\Delta\Delta C_t}$ (11).

Results

Classification of patients with DSD

Classical cytogenetic techniques were employed in order to categorize each patient into the correct DSD class according to the karyotype. Thirty-seven patients showed a 46,XX karyotype, while 46 patients had a 46,XY karyotype. Out of 88 patients, five ([Table 2](#), cases 1 to 5) showed an aberrant karyotype with mosaicism involving numerical and/or structural abnormalities of sex chromosomes. Those patients were then classified as affected by sex chromosome DSD. *SRY* absence/presence test, successively performed on the seven males showing a 46,XX karyotype, identified the *SRY* gene in two patients ([Table 2](#), cases 7 and 8). FISH analysis performed with a *SRY*-specific probe defined those patients' karyotype as 46,XX.ish der(X)(X;Y)(p22.3;p11.3)(*SRY*+), indicative of whole *SRY* gene translocation to the X chromosome in both cases. In accordance with karyotyping and FISH analyses, our cohort was determined to be composed as shown in [Fig. 1](#). On the basis of subsequent clinical investigations, out of 88 patients, 29 (33%) were classified as carriers of a 46,XY disorder in androgen synthesis or action, 18 (20%) as carriers of a 46,XX disorder with androgen excess, 17 (19%) as carriers of 46,XY disorders of gonadal (testicular) development, 11 (13%) as affected by 46,XX DSD other, 8 (9%) as carriers of 46,XX disorders of gonadal (ovarian) development, and 5 (6%) as carriers of sex chromosome DSD.

DSD 46,XX disorders of ovarian development

Both the five 46,XX testicular (*SRY*-negative) patients and the single 46,XX ovotesticular patient with DSD ([Fig. 1](#)) were first analyzed by MLPA for the presence of copy number imbalances affecting *SOX9*, *NROB1*, *NR5A1*, *SRY*, *CYP21A2*, and *WNT4* genes. In a single individual with 46,XX testicular DSD ([Table 2](#), case 9), we identified a heterozygous duplication encompassing *SOX9* exon 1.

The five 46,XX testicular (*SRY*-negative) patients and the single 46,XX ovotesticular patient with DSD ([Fig. 1](#)) were then investigated for the presence of *RSPO1* point mutations. We identified the homozygous c.286+1G>A (p.I32_I95del) splicing mutation in case 6 ([Table 2](#)). This patient was affected by 46,XX ovotesticular DSD associated with palmoplantar hyperkeratosis, congenital bilateral corneal opacity, and strabismus and this has already been reported (12). In total, we did not find any genetic alteration in four out of seven 46,XX testicular patients with DSD.

DSD 46,XX androgen excess

Eighteen 46,XX female patients with suspected adrenogenital syndrome derived from 21-hydroxylase enzyme deficiency ([Fig. 1](#)) were analyzed for *CYP21A2* gene mutations. One of these patients, in whom the hormonal profile was indicative of a rare form of the disease, was secondly analyzed for *CYP11B1* point mutations. In total, we found *CYP21A2* DNA alterations in 14 out of 18 (78%) patients ([Table 2](#), cases 10–23). Among the seven different identified *CYP21A2* mutations, the c.293-13C/A>G change was present in heterozygosity in six out of 14 patients and in the homozygous condition in patient 10 ([Table 2](#)). *CYP21A2* large deletion/conversion was detected in heterozygosity in six out of 14 cases and in homozygosity in three out of 13 patients ([Table 2](#)). Out of 14 individuals, 8 (57%) were compound heterozygous for *CYP21A2* mutations, while six out of 14 (43%) were homozygous ([Table 2](#)). Parental DNA for cases 16 and 22 ([Table 2](#)) was available for determination of the origin of the mutations. *CYP21A2* del/conv was paternally derived in patient 16, while the mother harbored the c.293-13C/A>G mutation. Regarding patient 22, the c.920_921insT (p.L307insT) and the c.293-13C/A>G alterations were inherited, respectively, from the mother and the father. The result of the *CYP11B1* test indicated that the single analyzed patient ([Table 2](#), case 24) was homozygous for the p.G379V mutation. All the identified pathogenetic alterations have been reported previously (13, 14, 15, 16, 17, 18), except for *CYP21A2* c.365T>C (p.L122P) that was found to be novel.

DSD 46,XX, other (Mullerian Renal Cervicothoracic Somite association and Mayer Rokitansky Küster Hauser syndrome)

The single Mullerian Renal Cervicothoracic Somite (MURCS) and the ten Mayer Rokitansky Küster Hauser (MRKH) individuals ([Fig. 1](#)), demonstrated to be negative in a previously performed array comparative genomic

Table 2 Clinical and genetic features of DSD mutated patients. The mutations not marked by any symbol were identified in heterozygosity/hemizyosity

Karyotype	Disorder of sex development	Patient	Genes	Mutations	References
mos 45,X(7)/47,X,idelc(Y)(q12), +mar:ish der(Y)(DYZ1+)(17)/ 46,X,idelc(Y)(q12)(76) mos 46,X(20)/45,XY(80) mos 45,X(70)/46,X,idelc(Y) (qter → p11.3::p11.3 → qter)(30) 45,X,(51)/46,X,idelc(Y)(q11.23)(49) 45,X(23)/46,XY(77) 46,XX	Sex chromosome	1			
46,XX,ish der(X)(X;Y)(p22.3;p11.3) (SRY+)	Disorders of ovarian development	2			
46,XX		3			
46,XX		4			
46,XX		5			
46,XX		6	RSPO1	c.286+1G>A (p.I32_I95del) [§]	(12)
46,XX		7, 8	SRY	Entire gene traslocation to chrX	(20)
46,XX		9	SOX9	Exon 1 duplication	This report (31)
46,XX		10	CYP21A2	c.293-13C/A>G [§]	(16)
46,XX		11	CYP21A2	del/conv	(13)
46,XX		12, 13, 14	CYP21A2	c.515T>A (p.I172N)	(16)
46,XX		15, 16, 17	CYP21A2	del/conv	(16)
46,XX		18	CYP21A2	c.293-13C/A>G	(17)
46,XX		19	CYP21A2	c.1214G>A (p.W405X)	(15)
46,XX		20	CYP21A2	del/conv	(16)
46,XX		21	CYP21A2	c.365T>C (p.L122P)	This report (13)
46,XX		22	CYP21A2	c.515T>A (p.I172N) [§]	(18)
46,XX		23	CYP21A2	c.952C>T (p.Q318X) [§]	(17)
46,XX		24	CYP21A2	c.293-13C/A>G	(31)
46,XX		25	CYP21A2	c.920_921insT (p.L307insT)	(16)
46,XX		26	CYP21A2	del/conv	(18)
46,XX		27	CYP21A2	c.952C>T (p.Q318X) [§]	(14)
46,XX		28	SHOX	Exon 6 duplication	This report (32)
46,XX		29	SHOX	Exon 6 duplication	This report (32)
46,XX		30	NR5A1	c.301C>G (p.L101V)	(33)
46,XX		31	NR5A1	c.691_699 dupCTACAGCTG	(19)
46,XX		32	DMRT1	(p.L231_L233dup) c.86C>T (p.T29M) c.872_874delITGG (p.V291del) Entire gene deletion	This report (34)

Table 2 Continued

Karyotype	Disorder of sex development	Patient	Genes	Mutations	References
46,XY	Disorders in androgen synthesis or action	33	AR	c.1641C>G (p.L547F)	(35)
		34	AR	c.2290_2291inv.TA (c.2290A>T;2291T>A), p.Y763I)	This report
		35	AR	c.2491C>T (p.R831X)	(36)
		36	AR	c.2718C>T (p.R786X)	(37)
		37	AR	c.2417G>A (p.C806Y)	(38)
		38	AR	c.2665G>A (p.V889M)	(39)
		39	AR	c.1249delG (p.A417Rfs*61)	This report
		40	AR	c.1820G>A (p.R607Q)	(40)
		41	AR	c.2296G>A (p.A766T)	(41)
		42, 43, 44	AR	c.1886-2A>G	This report
		45	AR	c.906delC (p.S302Rfs*19)	This report
		46	AR	c.1769-13T>G	This report
		47	AR	c.165_788del (p.L56_L263del)	This report
		48	SRD5A2	c.158G>A (p.W53X)	(42)
				c.704A>T (p.Y235F)	(43)
		49	SRD5A2	c.397T>G (p.C133G) [§]	(44)
		50	SRD5A2	c.586G>A (p.G196S)	(45)
				c.1036A>T (p.R246W)	(46)
		51	SRD5A2	c.513G>C (p.R171S)	(47)
				c.763T>C (p.X255Qfs*28)	(48)
		52	SRD5A2	c.513G>C (p.R171S)	(47)
				c.586G>A (p.G196S)	(46)
		53, 54	SRD5A2	c.332_333delTC (p.L111Hfs*24)	This report
				c.620C>A (p.A207D)	(49)
		55	SRD5A2	c.377A>G (p.Q126R)	(47)
				c.1036A>T (p.R246W)	(46)
		56	AMH	c.367C>T (p.R123W)	(50)
				c.564C>A (p.C188X)	This report

MRKH, Mayer-Rokitansky-Kuster-Hauser; del/cony, deletion/conversion.
[§]Homozygous mutations. The mutations not marked by any symbol were identified in heterozygosity/hemizygoty.

Figure 1

Etiological classification of 88 patients with DSD. After karyotyping and *SRY*-specific FISH analyses, the patients were classified using the classes suggested by Hughes et al. (1). MURCS, Müllerian aplasia, Renal aplasia,

and Cervico-thoracic Somite dysplasia; MRKH, Mayer-Rokitansky-Kuster-Hauser; CGD, Complete Gonadal Dysgenesis; PGD, Partial Gonadal Dysgenesis.

hybridization analyses (data not shown), were analyzed for the presence of *WNT4* point mutations and for *SHOX* copy number imbalances. None of the patients were found to carry a *WNT4* alteration, while a duplication of *SHOX* exon 6 in the heterozygous state was found in two out of ten MTKH patients (Table 2, cases 25–26).

DSD 46,XY disorders of testicular development

Seventeen 46,XY patients (Fig. 1) were studied for variations in the *SRY*, *NR5A1*, and *DHH* genes. We identified the heterozygous c.301C>G (p.L101V) *SRY* missense mutation in patient 28 (Table 2) manifesting complete gonadal dysgenesis. Three patients with partial gonadal dysgenesis were heterozygous carriers of three different *NR5A1* mutations: c.691_699 dupCTACAGCTG (p.L231_L233dup) (19) (Table 2, patient 29), c.86C>T (p.T29M) (Table 2, patient 30), and c.872_874delTGG (p.V291del) (Table 2, patient 31). None of the *DHH* point mutations were found in the analyzed patients. Following *SRY*, *NR5A1*, and *DHH* screening, the 13 out of 17 negative cases were tested for copy number alterations in *NROB1*, *WNT4* and *DMRT1* genes. Patient 27 (Table 2) showing complete gonadal dysgenesis carried a heterozygous whole *NROB1* gene duplication. We identified a heterozygous deletion encompassing the *DMRT1* gene in patient 32 (Table 2) manifesting partial gonadal dysgenesis. Finally, we did not detect a *WNT4* imbalance in any of the investigated patients.

DSD 46,XY disorders in androgen synthesis or action

Sequence analysis of *AR* and *SRD5A2* genes was performed in 29 patients with suspected DSD 46,XY defects in the

synthesis or action of androgens (Fig. 1). The *AMH* gene was sequenced in a single case with the clinical diagnosis of persistent Müllerian duct syndrome. We found a genetic alteration in 24 out of 29 (83%) patients (Fig. 2). Among them, 15 individuals (Table 2, cases 33–47) were found to carry a hemizygous mutation in the *AR* gene. Out of 13 identified different sequence changes, six were missense mutations, five were truncating mutations, and two were splicing mutations. The c.1886-2A>G splicing alteration was detected in three unrelated patients (Table 2, cases 42–44). Six identified *AR* alterations were first reported in this study (c.906delC (p.S302Rfs*19), c.1249delG (p.A417Rfs*61), c.1769-13T>G, c.1886-2A>G, c.2290_2291inv.TA (c.(2290A>T;2291T>A), p.Y763I),

Figure 2

Point mutation analysis of *AR*, *SRD5A2*, and *AMH* genes in 29 patients with 46,XY DSD disorders in androgen synthesis or action. Out of 29 patients, 15 (52%) harbored a mutation in the *AR* gene, 8 (27%) in the *SRD5A2* gene, and 1 (3%) in the *AMH* gene. Out of the 29 patients, 5 (17%) did not show any point mutations in the coding sequences of the analyzed genes.

and c.165_788del (p.L56_L263del)). Eight patients carried a total of 12 different alterations in the *SRD5A2* gene in compound heterozygosity (Table 2, cases 48 and 50–55) or in the homozygous state (Table 2, case 49). Out of 12 mutations, eight were missense, while four were truncating. Three missense mutations recurred in more than one patient: c.513G>C (p.R171S) (Table 2, cases 51 and 52), c.586G>A (p.G196S) (Table 2, cases 50 and 51), and c.1036A>T (p.R246W) (Table 2, cases 50 and 55). The c.513G>C (p.R171S) and the c.763T>C (p.X255Qfs*28) were, respectively, paternally and maternally derived in

patient 51. Two of the identified alterations (c.564C>A (p.C188X) and c.332_333delTC (p.L111Hfs*24)) were found to be novel. Finally, a single patient (Table 2, case 56) was a compound heterozygote for a missense (c.367C>T (p.R123W)) and a novel nonsense (c.564C>A (p.C188X)) mutation in the *AMH* gene.

In total, we found a genetic alteration in 56 out of 88 (64%) patients (Table 2). Figure 3 summarizes the genetic tests, and the respective results, performed on patients with 46,XX disorders of ovarian development, 46,XX androgen excess, 46,XX other, 46,XY disorders of

Figure 3

Genetic studies and molecular results for 83 patients with 46,XX and disorders of ovarian development, 46,XX and androgen excess, 46,XX other, 46,XY and disorders of testicular development, and 46,XY and disorders in androgen synthesis or action. DSD clinical classes and genetic tests performed are listed on the y-axis. For each molecular analysis, the

number of positive (mutated) and negative (not mutated) patients is symbolized by gray bars. *SRY* +/-, *SRY* presence/absence test; MLPA Intersex: MLPA SALSA P185-B2 Intersex; *RSPO1*, *CYP21A2*, *CYP11B1*, *WNT4*, *SHOX*, *SRY*, *NR5A1*, *DHH*, *DMRT1*, and *SRD5A2*, molecular study of the listed genes.

Figure 4

Positions of the identified point mutations along the coding sequences of the *SRY*, *AMH*, *SRD5A2*, *NR5A1*, *CYP11B1*, *AR*, *RSPO1*, and *CYP21A2* genes. Exons are symbolized by gray boxes and introns (not in scale) by black lines. Functional protein domains are represented by black stripes above each

gene diagram. HMG, High-Mobility Group; TGFB, transforming growth factor Beta; ZnF_C4, c4 zinc finger; HOLI, ligand-binding domain of hormone receptors; FU, furin-like repeats; TSP1, thrombospondin type 1 repeats. Protein domains were predicted using the SMART software (30).

testicular development, and 46,XY disorders in androgen synthesis/action. The positions of all the identified point mutations along the *SRY*, *AMH*, *SRD5A2*, *NR5A1*, *CYP11B1*, *AR*, *RSPO1*, and *CYP21A2* coding sequences are shown in Fig. 4.

Discussion

DSDs are complex conditions related to a vast number of different causes. Establishing the specific etiology may be crucial for choosing the more adequate sex of assignment, for the clinical management of patients, and to permit the family to plan informed further pregnancies. However, molecular characterization cannot be reached in a consistent number of cases, due to the still limited

knowledge of etiological determinants. In this report, we describe the clinical assessment and the cytogenetic and molecular findings in a large cohort of patients with DSD. In our hands, it was possible to identify a genetic defect in 64% of them and to assign each of the examined patients to a specific category in accordance with the current DSD classification. Accordingly, a specific survey could be planned for each patient. This study excluded 45,X as well as 47,XXX and 47,XXY patients and individuals with sex chromosome mosaicism identified during prenatal diagnosis, but that did not display abnormalities of the genital tract after birth. Karyotype analysis performed during this study showed that five out of 88 (6%) patients harbored mosaic sex chromosome anomalies, confirming that standard cytogenetic analyses can detect frequent

genetic causes of DSD. Moreover, the initial classification based on clinical and cytogenetic findings was revealed to be an important starting point to carry out the further appropriate molecular testing, specific for each DSD subgroup. Out of 88 patients, 7 (8%) were classified as 46,XX testicular DSD and, between them, two out of seven carried a *SRY* translocation onto the pseudoautosomal region PAR1 of one X chromosome. This aberration is considered the major cause of testicular development in individuals with 46,XX testicular DSD (20, 21, 22). Conversely *SRY* translocation appeared to be involved only in less than a third of our cases. Thus, we assumed that other molecular determinants were responsible for the other 46,XX testicular DSD cases not carrying the *SRY* translocation. The involvement of the *SOX9* gene has already been demonstrated in a number of 46,XX testicular patients with DSD (5, 23, 24). Particularly, Cox et al. (24) and Vetro et al. (5) reported a 178-kb duplication and a 96 kb triplication, respectively, 600kb and 500 kb upstream of *SOX9*, in 46,XX, *SRY*-negative male patients. These alterations were assumed to enhance the promoter activity leading to *SOX9* overexpression. In this study, we demonstrated the presence of a *SOX9* exon 1 duplication in a 46,XX testicular patient with DSD (Table 2, case 9) not harboring an *SRY* translocation. Although it is not possible to affirm with certainty that the duplication identified in our patient is causative of his DSD, data from the literature permit speculation about its role in the determination of the abnormal gonadal development (5, 23, 24). Owing to the lack of the patient's DNA, it was not possible to investigate whether the rearrangement identified in case 9 extended upstream of *SOX9*, but we cannot exclude the involvement of its promoter. In addition, as patient 9 belongs to north African ethnic group and lives in Africa, DNA neither from other family members nor from healthy controls of his population was available for testing the origin and the possible recurrence of the rearrangement. Our series of *SRY*-negative 46,XX testicular patients with DSD were also investigated for *RSPO1* gene alterations as this gene has already been described as recessively mutated in two familial cases with 46,XX testicular DSD (25). Those patients showed genital anomalies accompanied by additional features, in particular palmoplantar hyperkeratosis. We did not find any *RSPO1* point mutations in our 46,XX testicular DSD cases, implying that the *RSPO1* gene may not be involved in 46,XX testicular DSD without palmoplantar hyperkeratosis. Our series of patients included a single 46,XX ovotesticular DSD case showing palmoplantar hyperkeratosis. This patient was born from consanguineous parents and

harbored the c.286+1G>A (p.I32_I95del) *RSPO1* mutation in homozygosity (12).

The 21-hydroxylase deficiency is considered the most frequent cause of DSD with genital ambiguity. Genetic analysis of *CYP21A2* performed in patients with a definitive or presumptive clinical diagnosis of adrenogenital syndrome allowed the identification of the molecular defect in 14 out of 18 (78%) cases. Among the four negative patients, case 24 was afterward recognized to be affected by a very rare form of congenital adrenal hyperplasia related to 11- β -hydroxylase deficiency. This patient was born as the result of a consanguineous mating and presented ambiguous genitalia at birth. Her clinical and hormonal profile could be defined only after the first weeks of life, when the *CYP21A2* study had already been started. She was found to carry the homozygous p.G379V alteration in the *CYP11B1* gene. The remaining three out of 18 *CYP21A2*-negative patients, in whom adrenogenital syndrome was suspected, showed regression of clitoral hypertrophy throughout the late neonatal period. The evolution of their clinical presentation together with the molecular and hormonal findings led to definitive exclusion of the initial diagnostic hypothesis in these infants.

Regarding 46,XX patients with DSD with abnormal development of the Müllerian structures, our results demonstrated the presence of a duplication involving *SHOX* exon 6 in two out of ten unrelated cases with MRKH syndrome, a condition of still mostly unclear etiology. Nevertheless, our targeted investigations permitted replication of the results obtained from the study by Gervasini et al. (4), which reported a *SHOX* intragenic duplication in five patients with abnormal development of the Müllerian ducts. Although the mechanism that may relate *SHOX* duplications and the development of Müllerian ducts has not been clarified, our data and those described by Gervasini et al. (4) indicate a possible functional role of *SHOX* in the MRKH syndrome. Based on the results obtained from the study by Philibert et al. (26) describing a *WNT4* heterozygous mutation in four cases with MRKH syndrome and hyperandrogenism, we sequenced the *WNT4* gene in 46,XX patients with DSD with abnormal development of the Müllerian structures, but did not find any DNA alteration. In accordance with results from other studies reporting the absence of *WNT4* gene mutations in MRKH women (27, 28), it is possible that the involvement of this gene is restricted to cases with an atypical form of the syndrome.

Investigations of patients affected by 46,XY DSD with a defect in testicular development led to the molecular characterization of six out of 16 (37%) cases.

These outcomes are consistent with the still incomplete understanding of the molecular events that underlie testicular development, indicating the need to search for novel genes associated with gonadal dysgenesis in 46,XY patients. The *NR5A1* gene, studied in 46,XY patients with a diagnosis of partial gonadal dysgenesis, was found to be mutated in heterozygosity in 3 out of 8 (37%) cases. These results consistent with those described in recent reports that identify mutations in *NR5A1* as a major cause of 46,XY DSD with a defect in the testicular development. Among the three mutations identified in *NR5A1*, the genetic location of c.86C>T (p.T29M) seems to affect the binding of the protein to DNA, while p.L231_233dup and p.V291 lay in the domain regulating transcription after hormone binding. Interestingly, in the three *NR5A1*-mutated patients, no Müllerian structures seemed to be present. The analysis of the *DHH* gene yielded negative results in all cases of 46,XY DSD with partial gonadal dysgenesis, even if *DHH* alterations have already been described as the possible cause of a consistent number of 46,XY DSD cases with a defect in the testicular development (29).

Concerning patients with 46,XY DSD with a defect in the synthesis or action of androgens, 24 out of 29 (83%) cases were characterized at a molecular level. Among the 12 different identified *SRD5A2* genetic alterations, one maps in the transmembrane region, possibly affecting the protein localization, and 11 in the protein catalytic domain. Sequence analysis of the *AR* gene identified 13 different mutations, including nine alterations lying in the functional protein domains: three out of nine in the zinc finger domain responsible for the DNA binding, and six out of nine in the domain that regulates the transcription after hormone binding. The incomplete diagnostic sensitivity of the applied molecular studies in 46,XY patients with DSD with a defect in the synthesis or action of androgens might be the cause of the failure of diagnosis in those partial androgen insensitivity syndrome (PAIS) patients for whom negative results were obtained according to *AR* analysis. These patients may indeed harbor DNA alterations in non-canonically investigated *AR* regions (introns or regulatory sequences), or in different known or as yet unidentified genes.

Our results highlight that each category of DSD is related to a large number of different DNA alterations, thus requiring multiple genetic studies to possibly achieve a precise etiological diagnosis in every patient. Currently, as a consequence of the incomplete knowledge concerning the genetic factors involved in the differentiation of testes and ovaries, DSD associated with anomalies in gonadal development still often lacks a molecular diagnosis.

A multidisciplinary and specialized DSD center is the key for the correct clinical management of neonates in cases of ambiguous genitalia. Moreover, the introduction of new technologies for massive parallel sequencing is becoming helpful for the molecular characterization of patients with DSD by analyzing previously known genes as well as candidate genes.

Supplementary data

This is linked to the online version of the paper at <http://dx.doi.org/10.1530/EC-14-0085>.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Author contribution statement

L Laino participated in the design and coordination of the study, carried out the cytogenetic studies, and drafted the manuscript; S Majore provided the genetic counseling to the patients, established the clinical diagnosis, participated in the study design, and helped to draft the manuscript; N Preziosi carried out the molecular genetic studies; B Grammatico participated in the design and helped to draft the manuscript; C De Bernardo participated in the design and helped to draft the manuscript; S Scommegna established the clinical diagnosis, participated in the study design, and helped to draft the manuscript; A M Rapone provided the psychological support to the families of the patients; G Marrocco conceived the study and gave the final approval of the version to be published; I Bottillo conceived the study, drafted the manuscript, and gave the final approval of the version to be published; and P Grammatico conceived the study and gave the final approval of the version to be published. All authors read and approved the final manuscript.

Acknowledgements

The authors thank all the families involved in this project.

References

- Hughes IA, Houk C, Ahmed SF, Lee PA, Group LC & Group EC. Consensus statement on management of intersex disorders. *Archives of Disease in Childhood* 2006 **91** 554–563. (doi:10.1136/adc.2006.098319)
- Vilain EJ. 46,XX testicular disorder of sex development. In *GeneReviews* 1993. Eds RA Pagon, MP Adam, HH Ardinger, TD Bird, CR Dolan, CT Fong, RJH Smith & K Stephens. Seattle (WA): University of Washington, Seattle.
- Ostrer H. 46,XY Disorder of Sex Development and 46,XY Complete Gonadal Dysgenesis. In *GeneReviews* 1993. Eds RA Pagon, MP Adam, HH Ardinger, TD Bird, CR Dolan, CT Fong, RJH Smith & K Stephens. Seattle (WA): University of Washington, Seattle.

- 4 Gervasini C, Grati FR, Lalatta F, Tabano S, Gentilin B, Colapietro P, De Toffol S, Frontino G, Motta F, Maitz S et al. *SHOX* duplications found in some cases with type I Mayer-Rokitansky-Kuster-Hauser syndrome. *Genetics in Medicine* 2010 **12** 634–640. (doi:10.1097/GIM.0b013e3181ed6185)
- 5 Vetro A, Ciccone R, Giorda R, Patricelli MG, Della Mina E, Forlino A & Zuffardi O. XX males *SRY* negative: a confirmed cause of infertility. *Journal of Medical Genetics* 2011 **48** 710–712. (doi:10.1136/jmedgenet-2011-100036)
- 6 Cui KH, Warnes GM, Jeffrey R & Matthews CD. Sex determination of preimplantation embryos by human testis-determining-gene amplification. *Lancet* 1994 **343** 79–82. (doi:10.1016/S0140-6736(94)90815-X)
- 7 Nishi MY, Domenice S, Maciel-Guerra AT, Zaba Neto A, Silva MA, Costa EM, Guerra-Junior G & Mendonca BB. Analysis of anti-Müllerian hormone (*AMH*) and its receptor (*AMHR2*) genes in patients with persistent Müllerian duct syndrome. *Arquivos Brasileiros de Endocrinologia e Metabologia* 2012 **56** 473–478. (doi:10.1590/S0004-27302012000800002)
- 8 Sasaki G, Ogata T, Ishii T, Kosaki K, Sato S, Homma K, Takahashi T, Hasegawa T & Matsuo N. Micropenis and the *5 α -reductase-2* (*SRD5A2*) gene: mutation and V89L polymorphism analysis in 81 Japanese patients. *Journal of Clinical Endocrinology and Metabolism* 2003 **88** 3431–3436. (doi:10.1210/jc.2002-021415)
- 9 Xu Z, Chen W, Merke DP & McDonnell NB. Comprehensive mutation analysis of the *CYP21A2* gene: an efficient multistep approach to the molecular diagnosis of congenital adrenal hyperplasia. *Journal of Molecular Diagnostics* 2013 **15** 745–753. (doi:10.1016/j.jmoldx.2013.06.001)
- 10 Lee HH, Lee YJ, Chan P & Lin CY. Use of PCR-based amplification analysis as a substitute for the southern blot method for *CYP21* deletion detection in congenital adrenal hyperplasia. *Clinical Chemistry* 2004 **50** 1074–1076. (doi:10.1373/clinchem.2003.028597)
- 11 Livak KJ & Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta CT}$ method. *Methods* 2001 **25** 402–408. (doi:10.1006/meth.2001.1262)
- 12 Tomaselli S, Megiorni F, De Bernardo C, Felici A, Marrocco G, Maggiulli G, Grammatico B, Remotti D, Saccucci P, Valentini F et al. Syndromic true hermaphroditism due to an R-spondin1 (*RSP01*) homozygous mutation. *Human Mutation* 2008 **29** 220–226. (doi:10.1002/humu.20665)
- 13 Hsu LC, Hsu NC, Guzova JA, Guzov VM, Chang SF & Chung BC. The common I172N mutation causes conformational change of cytochrome P450c21 revealed by systematic mutation, kinetic, and structural studies. *Journal of Biological Chemistry* 1996 **271** 3306–3310. (doi:10.1074/jbc.271.6.3306)
- 14 Kharrat M, Trabelsi S, Chaabouni M, Maazoul F, Kraoua L, Ben Jemaa L, Gandoura N, Barsaoui S, Morel Y, M'Rad R et al. Only two mutations detected in 15 Tunisian patients with 11 β -hydroxylase deficiency: the p.Q356X and the novel p.G379V. *Clinical Genetics* 2010 **78** 398–401. (doi:10.1111/j.1399-0004.2010.01403.x)
- 15 Wedell A & Luthman H. Steroid 21-hydroxylase deficiency: two additional mutations in salt-wasting disease and rapid screening of disease-causing mutations. *Human Molecular Genetics* 1993 **2** 499–504. (doi:10.1093/hmg/2.5.499)
- 16 White PC, Vitek A, Dupont B & New MI. Characterization of frequent deletions causing steroid 21-hydroxylase deficiency. *PNAS* 1988 **85** 4436–4440. (doi:10.1073/pnas.85.12.4436)
- 17 Rodrigues NR, Dunham I, Yu CY, Carroll MC, Porter RR & Campbell RD. Molecular characterization of the HLA-linked steroid 21-hydroxylase B gene from an individual with congenital adrenal hyperplasia. *EMBO Journal* 1987 **6** 1653–1661.
- 18 Globerman H, Amor M, Parker KL, New MI & White PC. Nonsense mutation causing steroid 21-hydroxylase deficiency. *Journal of Clinical Investigation* 1988 **82** 139–144. (doi:10.1172/JCI113562)
- 19 Camats N, Pandey AV, Fernandez-Cancio M, Andaluz P, Janner M, Toran N, Moreno F, Bereket A, Akcay T, Garcia-Garcia E et al. Ten novel mutations in the *NR5A1* gene cause disordered sex development in 46,XY and ovarian insufficiency in 46,XX individuals. *Journal of Clinical Endocrinology and Metabolism* 2012 **97** E1294–E1306. (doi:10.1210/jc.2011-3169)
- 20 Abbas N, McElreavey K, Leconiat M, Vilain E, Jaubert F, Berger R, Nihoul-Fekete C, Rappaport R & Fellous M. Familial case of 46,XX male and 46,XX true hermaphrodite associated with a paternal-derived *SRY*-bearing X chromosome. *Comptes Rendus de l'Academie des Sciences* 1993 **316** 375–383.
- 21 Lopez M, Torres L, Mendez JP, Cervantes A, Perez-Palacios G, Erickson RP, Alfaro G & Kofman-Alfaro S. Clinical traits and molecular findings in 46,XX males. *Clinical Genetics* 1995 **48** 29–34. (doi:10.1111/j.1399-0004.1995.tb04050.x)
- 22 de la Chapelle A. The etiology of maleness in XX men. *Human Genetics* 1981 **58** 105–116. (doi:10.1007/BF00284157)
- 23 Huang B, Wang S, Ning Y, Lamb AN & Bartley J. Autosomal XX sex reversal caused by duplication of *SOX9*. *American Journal of Medical Genetics* 1999 **87** 349–353. (doi:10.1002/(SICI)1096-8628(19991203)87:4<349::AID-AJMG13>3.0.CO;2-N)
- 24 Cox JJ, Willatt L, Homfray T & Woods CG. A *SOX9* duplication and familial 46,XX developmental testicular disorder. *New England Journal of Medicine* 2011 **364** 91–93. (doi:10.1056/NEJMc1010311)
- 25 Camerino G, Parma P, Radi O & Valentini S. Sex determination and sex reversal. *Current Opinion in Genetics & Development* 2006 **16** 289–292. (doi:10.1016/j.gde.2006.04.014)
- 26 Philibert P, Bignon-Lauer A, Gueorguieva I, Stuckens C, Pienkowski C, Lebon-Labich B, Paris F & Sultan C. Molecular analysis of *WNT4* gene in four adolescent girls with müllerian duct abnormality and hyperandrogenism (atypical Mayer-Rokitansky-Kuster-Hauser syndrome). *Fertility and Sterility* 2011 **95** 2683–2686. (doi:10.1016/j.fertnstert.2011.01.152)
- 27 Ravel C, Lorenzo D, Dessolle L, Mandelbaum J, McElreavey K, Darai E & Siffroi JP. Mutational analysis of the *WNT* gene family in women with Mayer-Rokitansky-Kuster-Hauser syndrome. *Fertility and Sterility* 2009 **91** 1604–1607. (doi:10.1016/j.fertnstert.2008.12.006)
- 28 Chang X, Qin Y, Xu C, Li G, Zhao X & Chen ZJ. Mutations in *WNT4* are not responsible for Müllerian duct abnormalities in Chinese women. *Reproductive Biomedicine Online* 2012 **24** 630–633. (doi:10.1016/j.rbmo.2012.03.008)
- 29 Canto P, Vilchis F, Soderlund D, Reyes E & Mendez JP. A heterozygous mutation in the *desert hedgehog* gene in patients with mixed gonadal dysgenesis. *Molecular Human Reproduction* 2005 **11** 833–836. (doi:10.1093/molehr/gah216)
- 30 Letunic I, Doerks T & Bork P. SMART 7: recent updates to the protein domain annotation resource. *Nucleic Acids Research* 2012 **40** D302–D305. (doi:10.1093/nar/gkr931)
- 31 Wedell A, Stengler B & Luthman H. Characterization of mutations on the rare duplicated C4/CYP21 haplotype in steroid 21-hydroxylase deficiency. *Human Genetics* 1994 **94** 50–54. (doi:10.1007/BF02272841)
- 32 Domenice S, Correa RV, Costa EM, Nishi MY, Vilain E, Arnhold IJ & Mendonca BB. Mutations in the *SRY*, *DAX1*, *SF1* and *WNT4* genes in Brazilian sex-reversed patients. *Brazilian Journal of Medical and Biological Research* 2004 **37** 145–150. (doi:10.1590/S0100-879X2004000100020)
- 33 Battaglia F, Plotti F, Angelucci M, Aloisi A & Angioli R. Novel mutation of the sex-determining region on the Y chromosome in a 46,XY female patient with monolateral dysgerminoma: a case report. *Journal of Obstetrics and Gynaecology Research* 2013 **39** 442–445. (doi:10.1111/j.1447-0756.2012.01956.x)
- 34 Swinkels ME, Simons A, Smeets DF, Vissers LE, Veltman JA, Pfundt R, de Vries BB, Faas BH, Schrander-Stumpel CT, McCann E et al. Clinical and cytogenetic characterization of 13 Dutch patients with deletion 9p syndrome: Delineation of the critical region for a consensus phenotype. *American Journal of Medical Genetics. Part A* 2008 **146A** 1430–1438. (doi:10.1002/ajmg.a.32310)
- 35 Melo KF, Mendonca BB, Billerbeck AE, Costa EM, Inacio M, Silva FA, Leal AM, Latronico AC & Arnhold IJ. Clinical, hormonal, behavioral,

- and genetic characteristics of androgen insensitivity syndrome in a Brazilian cohort: five novel mutations in the androgen receptor gene. *Journal of Clinical Endocrinology and Metabolism* 2003 **88** 3241–3250. (doi:10.1210/jc.2002-021658)
- 36 Chen CP, Chern SR, Chen BF, Wang W & Hwu YM. Hamartoma in a pubertal patient with complete androgen insensitivity syndrome and R(831)X mutation of the androgen receptor gene. *Fertility and Sterility* 2000 **74** 182–183. (doi:10.1016/S0015-0282(00)00554-9)
 - 37 Ignacak M, Niedziela M & Trzeciak WH. Transition C2718T in the AR gene, resulting in generation of a termination codon and truncated form of the androgen receptor, causes complete androgen insensitivity syndrome. *Journal of Applied Genetics* 2002 **43** 109–114.
 - 38 Brown TR, Scherer PA, Chang YT, Migeon CJ, Ghirri P, Murolo K & Zhou Z. Molecular genetics of human androgen insensitivity. *European Journal of Pediatrics* 1993 **152** (Suppl 2) S62–S69. (doi:10.1007/BF02125442)
 - 39 Ghadessy FJ, Lim J, Abdullah AA, Panet-Raymond V, Choo CK, Lumbroso R, Tut TG, Gottlieb B, Pinsky L, Trifiro MA et al. Oligospermic infertility associated with an androgen receptor mutation that disrupts interdomain and coactivator (TIF2) interactions. *Journal of Clinical Investigation* 1999 **103** 1517–1525. (doi:10.1172/JCI4289)
 - 40 Wooster R, Mangion J, Eeles R, Smith S, Dowsett M, Averill D, Barrett-Lee P, Easton DF, Ponder BA & Stratton MR. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. *Nature Genetics* 1992 **2** 132–134. (doi:10.1038/ng1092-132)
 - 41 Ko TM, Yang YS, Wu MY, Kao CH, Hsu PM, Chuang SM & Lee TY. Complete androgen insensitivity syndrome. Molecular characterization in two Chinese women. *Journal of Reproductive Medicine* 1997 **42** 424–428.
 - 42 Baldinotti F, Majore S, Fogli A, Marrocco G, Ghirri P, Vuerich M, Tumini S, Boscherini B, Vetri M, Scommegna S et al. Molecular characterization of 6 unrelated Italian patients with 5 α -reductase type 2 deficiency. *Journal of Andrology* 2008 **29** 20–28. (doi:10.2164/jandrol.107.002592)
 - 43 Nicoletti A, Baldazzi L, Balsamo A, Barp L, Pirazzoli P, Gennari M, Radetti G, Cacciari E & Cicognani A. SRSY2 gene analysis in an Italian population of under-masculinized 46,XY subjects. *Clinical Endocrinology* 2005 **63** 375–380. (doi:10.1111/j.1365-2265.2005.02348.x)
 - 44 Mazen I, Gad YZ, Hafez M, Sultan C & Lumbroso S. Molecular analysis of 5 α -reductase type 2 gene in eight unrelated Egyptian children with suspected 5 α -reductase deficiency: prevalence of the G34R mutation. *Clinical Endocrinology* 2003 **58** 627–631. (doi:10.1046/j.1365-2265.2003.01763.x)
 - 45 Nordenskjöld A & Ivarsson SA. Molecular characterization of 5 α -reductase type 2 deficiency and fertility in a Swedish family. *Journal of Clinical Endocrinology and Metabolism* 1998 **83** 3236–3238. (doi:10.1210/jcem.83.9.5125)
 - 46 Thigpen AE, Davis DL, Milatovich A, Mendonca BB, Imperato-McGinley J, Griffin JE, Francke U, Wilson JD & Russell DW. Molecular genetics of steroid 5 α -reductase 2 deficiency. *Journal of Clinical Investigation* 1992 **90** 799–809. (doi:10.1172/JCI115954)
 - 47 Fernandez-Cancio M, Nistal M, Gracia R, Molina MA, Tovar JA, Esteban C, Carrascosa A & Audi L. Compound heterozygous mutations in the SRSY2 gene exon 4 in a male pseudohermaphrodite patient of Chinese origin. *Journal of Andrology* 2004 **25** 412–416. (doi:10.1002/j.1939-4640.2004.tb02808.x)
 - 48 Maimoun L, Philibert P, Cammas B, Audran F, Pienkowski C, Kurtz F, Heinrich C, Cartigny M & Sultan C. Undervirilization in XY newborns may hide a 5 α -reductase deficiency: report of three new SRSY2 gene mutations. *International Journal of Andrology* 2010 **33** 841–847. (doi:10.1111/j.1365-2605.2009.01036.x)
 - 49 Hackel C, Oliveira LE, Ferraz LF, Tonini MM, Silva DN, Toralles MB, Stuchi-Perez EG & Guerra-Junior G. New mutations, hotspots, and founder effects in Brazilian patients with steroid 5 α -reductase deficiency type 2. *Journal of Molecular Medicine* 2005 **83** 569–576. (doi:10.1007/s00109-005-0651-7)
 - 50 Imbeaud S, Carre-Eusebe D, Rey R, Belville C, Josso N & Picard JY. Molecular genetics of the persistent müllerian duct syndrome: a study of 19 families. *Human Molecular Genetics* 1994 **3** 125–131. (doi:10.1093/hmg/3.1.125)

Received in final form 16 September 2014

Accepted 23 September 2014